CLL: India's Lesser-Known Blood Cancer Explained

Chronic lymphocytic leukemia (CLL), a type of blood cancer affecting lymphocytes, is less common in India than in the United States, with incidence rates ten times lower. This slow-progressing leukemia is often discovered incidentally during regular blood tests, especially if lymphocyte counts are unusually high.

Diagnosis typically involves a complete blood count and peripheral blood film, with flow cytometry confirming the presence of abnormal B-lymphocytes. Further genetic tests like FISH or TP53 mutation analysis may be conducted for a detailed prognosis. While a bone marrow test isn't always necessary, it can be performed if deemed appropriate by a doctor.

Initially, CLL is often asymptomatic, with a key indicator being an elevated lymphocyte count. As the disease advances, symptoms such as swollen lymph nodes, unexplained weight loss, weakness, fever, anemia, and low platelet counts may develop. CLL is staged A, B, and C, reflecting symptom severity.

Treatment for CLL is individualized, depending on the disease stage, symptoms, and genetic makeup. Many early-stage, asymptomatic patients can be managed with a 'watch and wait' approach, involving regular monitoring. When treatment is required, targeted oral therapies like BTK and BCL2 inhibitors, sometimes combined with antibodies, are common, with molecular markers guiding therapy decisions to control the disease while preserving quality of life.